Given a passage with a context and an answer, construct a question on the basis of the information present in the passage. Construct the question in such a way that (i) it is unambiguous, (ii) it is answerable from the passage, (iii) its answer is unique (iv) it answer uses text phrases from the passage. Avoid creating questions that (i) can't be answered correctly without actually understanding the passage and (ii) uses the same words or phrases given in the passage.

Example Input: Context: We utilized whole-genome mapping of promoters that are activated by DNA hypomethylation in hepatocellular carcinoma (HCC) clinical samples to shortlist novel targets for anticancer therapeutics. We provide a proof of principle of this approach by testing six genes short-listed in our screen for their essential role in cancer growth and invasiveness.', 'We used siRNA- or shRNA-mediated depletion to determine whether inhibition of these genes would reduce human tumor xenograft growth in mice as well as cell viability, anchorage-independent growth, invasive capacities, and state of activity of nodal signaling pathways in liver, breast, and bladder cancer cell lines.', 'Depletion of EXOSC4, RNMT, SENP6, WBSCR22, RASAL2, and NENF effectively and specifically inhibits cancer cell growth and cell invasive capacities in different types of cancer, but, remarkably, there is no effect on normal cell growth, suggesting a ubiquitous causal role for these genes in driving cancer growth and metastasis. Depletion of RASAL2 and NENF in vitro reduces their growth as explants in vivo in mice. RASAL2 and NENF depletion interferes with AKT, WNT, and MAPK signaling pathways as well as regulation of epigenetic proteins that were previously demonstrated to drive cancer growth and metastasis.
Answer: Our results prove that genes that are hypomethylated and induced in tumors are candidate targets for anticancer therapeutics in multiple cancer cell types. Because these genes are particularly activated in cancer, they constitute a group of targets for specific pharmacologic inhibitors of cancer and cancer metastasis. Clin Cancer Res; 20(12); 3118-32. ©2014 AACR.
Example Output: Does genome-wide study of hypomethylated and induced genes in patients with liver cancer unravel novel anticancer targets?

Example Input: Context: This study was designed to investigate the effects of simvastatin in a rat model of acute myocardial infarction.', 'Male Wistar rats were anesthetized (thiopentone sodium 120 mg/kg). After a thoracotomy, the left-anterior-descending coronary artery (LAD) was occluded (for 25 min) and reperfused (for 120 min). Area at risk (AR) was determined with Evans Blue dye and infarct size after staining of the area at risk with nitroblue tetrazolium.', 'In rats, which received the vehicle for simvastatin (10% DMSO, 1 ml/kg i.v. at 1 h prior to the occlusion of the LAD), occlusion of the LAD for 25 min followed by reperfusion for 2 hours resulted in an infarct size of 54 +/- 4% (n=7) of the AR. When compared with vehicle, administration of simvastatin (1 mg/kg i.v. bolus administration at 1 h prior to the onset of myocardial ischemia) caused a significant reduction in myocardial infarct size of 39%. LAD-occlusion and reperfusion caused a progressive fall in mean arterial blood pressure (when compared with sham-operated animals). Simvastatin had no significant effect on blood pressure.
Answer: The result indicates that simvastatin, an inhibitor of HMG-CoA reductase and a ligand of PPAR-a and PPAR-g, reduces the tissue necrosis associated with acute myocardial infarction. We propose that statins may be useful in conditions associated with ischemia-reperfusion of the heart and other organs.
Example Output: Does simvastatin reduce infarct size in a model of acute myocardial ischemia and reperfusion in the rat?

Example Input: Context: The safety of a potential AIDS vaccine is an issue that will become critical at later stages of product development and needs to be addressed before it is too late.', 'In order to design safer vaccine, the HIV antigens, to be deployed in it, should be free of regions that are either present in human proteins or exhibit pronounced structural similarity to proteins responsible for important physiological functions.', 'The approach is based on the use of an original matrix predicting the antigenic similarity of amino acids. This mathematical approach developed by us was applied for identification of fragments with similarity to human proteins within potentially immunodominant regions of HIV proteins. A potential self-sensitization by viral quasispecies with variants of hypervariable V3 region, generated as a result of immune pressure on the immunodominant region of envelope, was considered in detail.', 'Viral fragments occurring in normal human proteins as well as regions exhibiting high similarity to proteins responsible for physiological homeostasis were identified in every HIV protein at a frequency higher than expected. Most such regions contained either T-cell (CD8(+) CTL or CD4(+) Helper) or B-cell epitopes, or both of them simultaneously. The gained knowledge was applied in designing a synthetic immunogen containing multiple CTL epitopes. The synthesis of series of chimeric peptides representing hypervariable region of V3 loop of HIV envelope, to be used as a multi-epitope or mixotope vaccine candidate, has been achieved. Such a vaccine could theoretically pre-empt any escape mutant borrowing from antigenic diversity of hypervariable region of V3 loop of HIV envelope.
Answer: The epitopes shared by HIV and its host are likely to be implicated in the immunopathogenesis of AIDS through induction of cross-reacting effectors of the immune system. The prospect that 'house-keeping' immune mechanism can be foiled by molecular mimicry of HIV with physiologically important human proteins should be taken into consideration in safer vaccine design.
Example Output:
Is exclusion of HIV epitopes shared with human proteins prerequisite for designing safer AIDS vaccines?